Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Insite Vision Inc. -- Ignore unavailable to you. Want to Upgrade?

To: NYBellBoy who wrote (887)	11/10/1998 11:10:00 AM
From: Kushi Kullar	Respond to of 1060

Well unfortunately the article had no real effect on the stock price. Perhaps the operating assumption is they will never get it to market. Their track record would certainly justify this conclusion.

To: NYBellBoy who wrote (887)	11/10/1998 12:12:00 PM
From: Ron Oda	Read Replies (2) \| Respond to of 1060

Here is the IBD article: investors.com You can use Username: CHOOSE Password: SUCCEED (all caps) The article is not specifically about Insite but basically talks about Insite's Gene diagnostic stuff and about some treatments. Then towards the end they mention Insite: ** The genetic tests and the new neuroprotective drugs are in clinical trials throughout the country. Companies involved in the research and development of these products include Insite Vision Inc. of Alameda, Calif., and Allergan Inc. of Irvine, Calif. ** This could have been real positive for Insite if they had been mentioned earlier in the article. As it is, people won't know if the Gene stuff is Insite's or Allergan's. At the end it mentions that the drugs won't be available for years. This is not the case with the diagnostic kit, but to those who don't know about the kit, they will think it is years away. Still, it is positive and we will see what happens. RG